Coloplast Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Coloplast şirketinin toplam hissedar öz sermayesi DKK7.0B ve toplam borcu DKK20.8B olup, bu da borç-öz sermaye oranını 295.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK35.3B ve DKK28.3B dir. Coloplast 'in FAVÖK'ü DKK7.0B faiz karşılama oranı 18.9 dur. Şirketin DKK644.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

295.4%

Borç/özkaynak oranı

DKK 20.78b

Borç

Faiz karşılama oranı	18.9x
Nakit	DKK 644.00m
Eşitlik	DKK 7.03b
Toplam yükümlülükler	DKK 28.27b
Toplam varlıklar	DKK 35.30b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0QBO N 'nin kısa vadeli varlıkları ( DKK9.3B ) kısa vadeli yükümlülüklerini ( DKK9.4B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 0QBO N 'un kısa vadeli varlıkları ( DKK9.3B ) uzun vadeli yükümlülüklerini ( DKK18.8B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0QBO N 'nin net borç/öz sermaye oranı ( 286.3% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 0QBO N şirketinin borç/öz sermaye oranı son 5 yılda 59.2% seviyesinden 295.4% seviyesine yükseldi.

Borç Kapsamı: 0QBO N 'nin borcu işletme nakit akışı ( 23.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 0QBO N 'in borcuna ilişkin faiz ödemeleri EBIT ( 18.9 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Coloplast Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin